U.S. Markets open in 6 hrs 43 mins
  • S&P Futures

    3,830.50
    -15.50 (-0.40%)
     
  • Dow Futures

    30,931.00
    -151.00 (-0.49%)
     
  • Nasdaq Futures

    13,350.75
    -44.75 (-0.33%)
     
  • Russell 2000 Futures

    2,132.20
    -6.30 (-0.29%)
     
  • Crude Oil

    52.47
    -0.66 (-1.24%)
     
  • Gold

    1,859.10
    -6.80 (-0.36%)
     
  • Silver

    25.53
    -0.32 (-1.23%)
     
  • EUR/USD

    1.2162
    -0.0010 (-0.0851%)
     
  • 10-Yr Bond

    1.1090
    0.0000 (0.00%)
     
  • Vix

    21.32
    -0.26 (-1.20%)
     
  • GBP/USD

    1.3674
    -0.0057 (-0.4143%)
     
  • USD/JPY

    103.6660
    +0.1610 (+0.1556%)
     
  • BTC-USD

    30,919.41
    +351.70 (+1.15%)
     
  • CMC Crypto 200

    612.02
    +2.02 (+0.33%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet

·2 min read
Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo

BENGALURU (Reuters) - Glenmark Pharmaceuticals Ltd said on Monday it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees ($0.9983) per tablet for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India.

Glenmark last month received Indian regulatory approval to make and sell anti-flu drug favipiravir, which is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp.

Glenmark had priced FabiFlu at 103 rupees per tablet earlier, making it one of the cheapest COVID-19 treatment available in the country.

"Glenmark's price reduction aims to make FabiFlu further accessible for COVID-19 patients across the country," the company said in a statement https://reut.rs/3iZSbrJ.

The price reduction comes at a time when coronavirus cases are continuing to surge across India. The country registered a record increase in infections on Sunday, and has over 870,000 cases as of Monday, with the death toll at 23,174, according to federal health ministry data https://bit.ly/2VPOFGm.

Social media users have also complained of a shortage of COVID-19 treatment in the nation.

A treatment course with FabiFlu would require a patient to take 122 tablets over 14 days, and will now cost 8,475 rupees ($112.80) per patient at the new price.

Meanwhile, Japanese researchers on Friday said a clinical trial of Fujifilm's Avigan yielded inconclusive results as a treatment for COVID-19.

Dr.Reddy's Laboratories Ltd has entered into a deal with Fujifilm to sell Avigan globally excluding Japan, China and Russia.

Mumbai-based Glenmark has also commenced a post marketing surveillance study with FabiFlu to monitor its efficacy and safety in 1,000 patients that are prescribed with the oral antiviral, the company said.

($1 = 75.1300 Indian rupees)

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi Aich)